

# Supporting Materials

## Energy of the system





Figure S1: Energy of the simulated systems during the 500 ns production run. The red line shows the kinetic energy, and the blue line shows the potential energy. The green line shows the total energy.

## Ligand–P-gp interactions


		AMI <sup>1</sup>	CAR <sup>2</sup>	CSA <sup>3</sup>	DOX <sup>4</sup>	APD <sup>5</sup>	BUS <sup>6</sup>	GEN <sup>7</sup>	PQT <sup>8</sup>	VPA <sup>9</sup>
TM1	L65									
	M69									
TM3	Q195									
	A229									
TM4	W232									
	L236									
TM5	F303									
	I306									
	Y307									
	Y310		HB		HB			HB		
TM6	F336									
	L339									
	I340									
	F343									
TM7	S344									
	Q347									
	Q725									
	F728									
TM10	F732									
	E875					HB				
	M876									
	L879									
TM11	Q946									
	M949									
	Y950									
	Y953	HB		HB						
TM12	F983									
	M986									
	A987									
	Q990		HB	HB						

Interaction      HB      No interaction






Figure S1: Ligand–P-gp interactions. Residues involved in non-bonded and hydrogen bond contacts. <sup>1</sup> Amiodarone; <sup>2</sup> carvedilol; <sup>3</sup> cyclosporine A; <sup>4</sup> doxorubicin; <sup>5</sup> pamidronate; <sup>6</sup> busulfan; <sup>7</sup> gentamicin; <sup>8</sup> paraquat; <sup>9</sup> valproic acid.



(a)



(b)






Figure S3: 3D representation of the most relevant ligand–P-gp interactions within the binding pocket. (a) P-gp–AMI; (b) P-gp–CAR; (c) P-gp–CSA; (d) P-gp–DOX; (e) P-gp–APD; (f) P-gp–BUS; (g) P-gp–GEN; (h) P-gp–PQT; (i) P-gp–VPA. The binding pocket is shown in surface representation with a colour scheme corresponding to the hydrophobicity; non-polar regions are coloured in yellow. Residues involved in hydrogen bonding are exposed and highlighted with a dark blue mesh. Red arrows indicate hydrogen bond acceptor relationships, green arrows indicate hydrogen bond donor relationships, yellow spheres indicate hydrophobic interactions, and the blue ring indicates aromatic interactions.











Figure S4: BUS (magenta) and PQT (yellow) molecular surface representation of their different positions within the binding pocket during the 500 ns production run; (a) frontal view; (b) zoomed view; (c) view from the extracellular side of the protein looking into the inner chamber.

## Compounds properties


Table S1: 2D structures of the molecules used in the study.

Name	Chemical structure
Amiodarone	
Carvedilol	
Cyclosporine A	
Doxorubicin	
Pamidronate	
Busulfan	

Gentamicin



Paraquat



Valproic acid




Table S2: Physicochemical properties of the studied molecules

	LogP	HBD <sup>10</sup>	HBA <sup>11</sup>	TPSA <sup>12</sup> (Å <sup>2</sup> )	Heavy atom count	Aromatic rings
AMI <sup>1</sup>	7.57	0	4	42.7	31	3
CAR <sup>2</sup>	4.19	3	5	75.7	30	4
CSA <sup>3</sup>	2.92	5	12	279.0	85	0
DOX <sup>4</sup>	1.27	6	12	206.0	39	2
APD <sup>5</sup>	-4.70	6	8	161.0	13	0
BUS <sup>6</sup>	-0.52	0	6	104.0	14	0
GEN <sup>7</sup>	-3.10	8	12	200.0	33	0
PQT <sup>8</sup>	-4.22	0	0	7.8	14	2
VPA <sup>9</sup>	2.75	1	2	37.3	10	0

<sup>1</sup>Amiodarone; <sup>2</sup>carvedilol; <sup>3</sup>cyclosporine A; <sup>4</sup>doxorubicin; <sup>5</sup>pamidronate; <sup>6</sup>busulfan; <sup>7</sup>gentamicin; <sup>8</sup>paraquat; <sup>9</sup>valproic acid; <sup>10</sup>hydrogen bond donor count; <sup>11</sup>hydrogen bond acceptor count; <sup>12</sup>topological polar surface area.

## MM/PBSA free energies of binding

Table S3: Free energies of binding and the various MM/PBSA terms. Estimate of the overall binding free energies for the ligand-P-gp complexes studied, using MM/PBSA calculations.

Name	$\Delta G_{\text{Bind}}$ (kcal/mol)	$E_{\text{VDW}}$	$E_{\text{elec}}$	$G_{\text{non-polar}}$	$G_{\text{Disper}}$	$\Delta G_{\text{Gas}}$	$\Delta G_{\text{Solv}}$	$K_d$ calc ( $\mu\text{M}$ )	$K_d$ exp ( $\mu\text{M}$ )
CSA <sup>a</sup>	-55.09	-105.28	-19.47	-80.32	149.98	-124.75	69.66	$1.8 \times 10^{-34}$	0.2
AMI <sup>b</sup>	-31.23	-53.45	-10.36	-39.33	71.91	-63.81	32.58	$2.9 \times 10^{-17}$	2.0
CAR <sup>c</sup>	-23.96	-41.38	-10.67	-32.24	60.33	-52.05	28.09	$5.2 \times 10^{-12}$	0.3
DOX <sup>d</sup>	-24.79	-47.67	-9.85	-36.74	69.48	-57.53	32.74	$1.3 \times 10^{-12}$	4.4
GEN <sup>e</sup>	-20.04	-41.02	-7.53	-35.14	63.65	-48.54	28.51	$3.5 \times 10^{-9}$	-
BUS <sup>f</sup>	-12.77	-25.26	-3.29	-18.98	34.76	-28.55	15.78	$6.1 \times 10^{-4}$	-
APD <sup>g</sup>	-15.44	-21.12	-9.62	-14.84	30.14	-30.74	15.30	$7.2 \times 10^{-6}$	-
PQT <sup>h</sup>	-18.29	-20.03	-13.70	-15.09	30.54	-33.74	15.45	$6.4 \times 10^{-8}$	-
VPA <sup>i</sup>	-9.15	-17.79	-2.51	-15.44	26.59	-20.30	11.15	0.24	-

<sup>a</sup>Cyclosporine A; <sup>b</sup>amiodarone; <sup>c</sup>carvedilol; <sup>d</sup>doxorubicin; <sup>e</sup>gentamicin; <sup>f</sup>busulfan; <sup>g</sup>pamidronate; <sup>h</sup>paraquat; <sup>i</sup>valproic acid.

## NBDs distance




Figure S5: NBDs distance during the 500 ns production run. The separation was measured by the distance between the N atom in the Lys residue of the Walker A motif in NBD1 and the C $\alpha$  of the



Ser residue in the signature motif of NBD2.

## Principal Component Analysis




Figure S6: Cα-RMSF coloured representation for the P-gp–ligand systems along the principal components explaining at least 85% of the flexibility of the systems calculated from the 500 ns production run. The flexibility scale goes from cyan (lower values) to red (higher values).



## Modes of Motion of P-glycoprotein









Figure S7: Front and Cytoplasmic view of P-gp motion patterns along PC1; (a) P-gp-AMI; (b) P-gp-CAR; (c) P-gp-CSA. The direction of the movement is represented by magenta arrows and the size of the arrows is proportional to the magnitude of the movement. For clarity, the reverse direction is not shown.




(a)



(b)



(c)



(d)

Figure S8: Front and Cytoplasmic view of P-gp motion patterns along PC1; (a) P-gp-APD; (b) P-gp-BUS; (c) P-gp-GEN; (d) P-gp-PQT. The direction of the movement is represented by magenta arrows and the size of the arrows is proportional to the magnitude of the movement. For clarity, the reverse direction is not shown.




Figure S9: Front and Cytoplasmic view of P-gp motion patterns along PC1; (a) P-gp-DOX; (b) P-gp-VPA. The direction of the movement is represented by magenta arrows and the size of the arrows is proportional to the magnitude of the movement. For clarity, the reverse direction is not shown.

## Binding Pocket




Figure S102: Pocket shapes of the most-populated four cluster centroids for the active-bound systems; (a) front view; (b) zoomed view. The average pocket shape is shown as a blue surface. The additional regions that are more open or close than the average in each of the four clusters are shown as a green and red surface, respectively.




Figure S11: Pocket shapes of the most-populated five cluster centroids for the non-active-bound systems; (a) front view; (b) zoomed view. The average pocket shape is shown as a blue surface. The additional regions that are more open or close than the average in each of the five clusters are shown as a green and red surface, respectively. The cluster centroids are much more open than the average shape compared to the active-bound systems, confirming the higher fluctuations of the non-active compounds within the internal cavity.

## Solvent accessible surface area (SASA)

Table S4: Per residue SASA variations

Residue number	Average per residue SASA <sup>12</sup>								
	AMI <sup>1</sup>	CAR <sup>2</sup>	CSA <sup>3</sup>	DOX <sup>4</sup>	APD <sup>5</sup>	BUS <sup>6</sup>	GEN <sup>7</sup>	PQT <sup>8</sup>	VPA <sup>9</sup>
33	76.40	76.35	74.60	76.21	78.35	78.14	78.34	77.31	78.38
69	1.32	1.97	1.03	2.12	7.01	6.96	3.26	7.81	5.41
313	0.45	0.49	0.57	0.49	1.60	0.81	0.68	0.91	0.99
331	0.79	0.83	0.78	0.48	1.01	1.51	1.33	4.50	2.03
340	9.37	9.73	0.87	10.06	23.13	22.55	16.07	22.38	23.00
343	19.51	8.13	0.74	9.49	20.70	28.57	22.32	20.01	29.48
367	99.76	105.85	107.04	103.98	110.96	108.63	107.40	114.38	110.99
372	144.74	94.67	146.75	97.70	149.29	165.13	174.33	157.79	164.71
548	57.70	86.00	69.94	82.09	90.66	94.25	91.88	96.92	86.63
727	32.49	35.86	35.74	35.90	36.25	37.53	36.90	36.54	37.48
764	86.19	84.57	85.95	85.44	88.84	91.01	96.07	88.62	89.49
767	65.03	66.33	61.45	64.98	67.18	68.46	70.77	67.62	68.19
953	1.75	6.35	3.97	5.07	8.53	11.03	7.74	9.20	16.38
986	3.88	7.91	5.87	10.83	15.99	29.12	17.45	16.51	27.78

Residue number	Average per residue SASA <sup>12</sup>	
	Min(NA <sup>10</sup> ) - Max(A <sup>11</sup> )	% Decrease relative to Max(NA)
33	0.91	1.19
69	1.14	53.70
313	0.11	18.37
331	0.18	22.24
340	6.01	59.68
343	0.50	2.55
367	0.36	0.34
372	2.54	1.73
548	0.62	0.73
727	0.35	0.96
764	2.43	2.82
767	0.84	1.27
953	1.40	21.99
986	5.16	47.66

<sup>1</sup>P-gp-AMI; <sup>2</sup>P-gp-CAR; <sup>3</sup>P-gp-CSA; <sup>4</sup>P-gp-DOX; <sup>5</sup>P-gp-APD; <sup>6</sup>P-gp-BUS; <sup>7</sup>P-gp-GEN; <sup>8</sup>P-gp-PQT; <sup>9</sup>P-gp-VPA; <sup>10</sup>Non-active-bound system; <sup>11</sup>Active-bound system; <sup>12</sup>Solvent accessible surface area.

Table S5: Per residue SASA variations


Residue number	Average per residue SASA <sup>12</sup>								
	AMI <sup>1</sup>	CAR <sup>2</sup>	CSA <sup>3</sup>	DOX <sup>4</sup>	APD <sup>5</sup>	BUS <sup>6</sup>	GEN <sup>7</sup>	PQT <sup>8</sup>	VPA <sup>9</sup>
38	47.78	46.18	48.30	47.63	42.49	45.82	45.53	46.00	35.60
184	39.37	49.12	67.59	40.81	36.45	25.02	34.34	30.22	32.35
188	38.64	35.27	39.26	36.05	32.10	29.39	21.38	26.46	31.23
320	8.44	7.69	8.26	8.29	7.51	6.21	5.24	5.32	4.81
391	49.94	39.60	40.22	40.36	38.24	31.79	37.17	36.95	36.40
420	30.49	38.18	32.18	33.64	10.85	5.52	29.27	7.32	28.27
559	62.70	95.91	73.74	71.91	44.18	10.17	5.78	49.84	39.52
580	45.61	42.93	56.46	39.21	23.57	13.20	22.59	18.83	23.87
581	2.58	0.44	1.16	0.40	0.07	0.10	0.20	0.13	0.25
601	4.97	5.84	6.96	6.29	1.69	4.89	2.92	4.58	2.28
1021	118.28	147.02	126.67	138.48	90.40	108.25	109.98	86.89	103.94
1040	0.12	0.09	0.12	0.10	0.01	0.06	0.07	0.02	0.05
1049	102.06	125.42	111.60	117.66	80.14	94.11	87.75	85.74	88.55
1090	124.00	123.14	124.24	124.84	110.54	121.46	122.47	118.19	121.07
1154	2.03	0.86	0.96	0.99	0.41	0.66	0.67	0.83	0.72







Residue number	Average per residue SASA <sup>12</sup>	
	Min(A <sup>k</sup> ) - Max(NA <sup>j</sup> )	% Decrease relative to Max(NA)
38	0.18	0.40
184	2.91	7.99
188	3.16	9.85
320	0.18	2.37
391	1.36	3.55
420	1.22	4.17
559	12.86	25.80
580	15.35	64.29
581	0.15	58.04
601	0.08	1.68
1021	8.30	7.55
1040	0.02	28.27
1049	7.95	8.45
1090	0.67	0.55
1154	0.03	3.53







<sup>1</sup>P-gp-AMI; <sup>2</sup>P-gp-CAR; <sup>3</sup>P-gp-CSA; <sup>4</sup>P-gp-DOX; <sup>5</sup>P-gp-APD; <sup>6</sup>P-gp-BUS; <sup>7</sup>P-gp-GEN; <sup>8</sup>P-gp-PQT; <sup>9</sup>P-gp-VPA; <sup>10</sup>Non-active-bound system; <sup>11</sup>Active-bound system; <sup>12</sup>Solvent accessible surface area.









Metrics of the clustering analysis












Figure S12: Metrics used to select of the optimal number of clusters of each ligand-P-gp system. The dashed lines in the graph indicate the selected number of clusters.